<DOC>
	<DOC>NCT00507169</DOC>
	<brief_summary>The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine</brief_summary>
	<brief_title>SVT-40776 in Patients Suffering From Overactive Bladder Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<criteria>Patients suffering from OAB for at least 6 months prior to inclusion Pregnant and breastfeeding women Any medical condition or need for comedication which interferes with the drug under investigation (SVT40776) or the comparator (tolterodine)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>